Select Language
IL-17A
IL-17A Overview
| English Name | Interleukin 17A | Approved Drugs | 6 |
| Drugs in Clinical Trials | 28 | Target Synonym | Interleukin 17 (Cytotoxic T-Lymphocyte-Associated Serine Esterase 8)，CTLA8，IL17A，Interleukin 17A，Cytotoxic T-Lymphocyte-Associated Antigen 8，Cytotoxic T-Lymphocyte-Associated Protein 8，CTLA-8，IL-17A，IL-17，IL17，Interleukin-17A |
| Highest Development Stage | Approved | ||
| English Name | Interleukin 17A |
| Target Synonym | Interleukin 17 (Cytotoxic T-Lymphocyte-Associated Serine Esterase 8)，CTLA8，IL17A，Interleukin 17A，Cytotoxic T-Lymphocyte-Associated Antigen 8，Cytotoxic T-Lymphocyte-Associated Protein 8，CTLA-8，IL-17A，IL-17，IL17，Interleukin-17A |
| Approved Drugs | 6 |
| Drugs in Clinical Trials | 28 |
| Highest Development Stage | Approved |
IL-17A Product List
- Product Category
Protein (8)Kits (4)
- Product Status
Launched (11)In Research (1)
- Species
Mouse (1)Human (7)Cynomolgus (2)Canine (1)Rat (1)
- Tag
His Tag (5)His Tag & Avi Tag (2)Tag Free (1)- (4)
- Conjugate
Unconjugated (6)Biotin-labeled (2)- (4)
Add to Cart
Total: 12
- 1
- 2
IL-17A Background
Interleukin-17A (IL17A) is also known as cytotoxic T-lymphocyte-associated antigen 8 (CTLA8),which is a proinflammatory cytokine produced by activated T cells. IL17A can regulate the activities of NF-kappaB and mitogen-activated protein kinases. Also,IL17A can stimulate the expression of IL6 and cyclooxygenase-2 (PTGS2/COX-2), as well as enhance the production of nitric oxide (NO).Furthermore,IL17A has been found both in glycosylated and nonglycosylated forms. High levels of IL-17 are associated with several chronic inflammatory diseases including rheumatoid arthritis, psoriasis and multiple sclerosis.
IL-17A Synonyms
IL-17A,Interleukin-17A,CTLA-8,IL-17
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| HB-0017 | HB-0017; HB0017 | Phase 3 Clinical | HuaBo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co Ltd, Zhejiang Huahai Pharmaceutical Co Ltd | Arthritis, Psoriatic; Hidradenitis Suppurativa; Plaque psoriasis; Psoriasis; Spondylarthritis; Spondylitis, Ankylosing | Details |
| Izokibep | IMG-020; IMG020; ABY-035/AFO2; IMG-20; ABY-035; AFB-035 | Phase 3 Clinical | Affibody Ab | Arthritis, Psoriatic; Plaque psoriasis; Psoriasis; Spondylitis, Ankylosing | Details |
| Sonelokimab | ALX-0761; MSB-0010841; M-1095 | Phase 3 Clinical | Ablynx Nv | Arthritis, Psoriatic; Hidradenitis Suppurativa; Psoriasis | Details |
| Secukinumab Biosimilar(Celltrion) | CT-P55 | Phase 3 Clinical | Celltrion Inc | Multiple Sclerosis; Plaque psoriasis | Details |
| Secukinumab biosimilar (CSPC Pharmaceutical Group) | SYS6012; SYS-6012 | Phase 3 Clinical | CSPC Pharmaceutical Group Ltd | Plaque psoriasis | Details |
| SCT-650C | SCT650C; SCT-650-C; SCT-650C | Phase 3 Clinical | SinoCelltech Ltd | Arthritis, Rheumatoid; Autoimmune Diseases; Axial Spondyloarthritis; Hidradenitis Suppurativa; Plaque psoriasis; Spondylarthritis; Spondylitis, Ankylosing | Details |
| Secukinumab Biosimilar(Mabtech) | CMAB-015; CMAB015 | Phase 3 Clinical | Taizhou Mabtech Pharmaceutical Co Ltd | Plaque psoriasis; Psoriasis; Spondylitis, Ankylosing | Details |
| DMT-310 | DMT-310 | Phase 3 Clinical | Dermata | Acne Vulgaris; Rosacea | Details |
| Tibulizumab | LY-3090106; LY3090106; ZB-106 | Phase 2 Clinical | Eli Lilly And Company | Arthritis, Rheumatoid; Hidradenitis Suppurativa; Scleroderma, Systemic; Sjogren's Syndrome; Sjogren-Larsson Syndrome | Details |
| ORKA-002 | ORKA-002; PR-029; ORKA-021 | Phase 2 Clinical | Paragon Therapeutics Inc | Arthritis, Psoriatic; Plaque psoriasis; Psoriasis | Details |
| SIM-0335 | SIM-0335; SIM-335 | Phase 2 Clinical | BCY Pharm Co Ltd | Plaque psoriasis | Details |
| Simepdekinra | DC-853; LY4100511; LY-4100511 | Phase 2 Clinical | Dice Therapeutics Inc | Immune System Diseases; Plaque psoriasis | Details |
| Isomyosamine | MYMD-1 | Phase 2 Clinical | Mymd Pharmaceuticals Inc | Anxiety; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Depression; Frailty; Hashimoto Disease; Healthy Aging; Inflammation; Sarcopenia | Details |
| ZL-1102 | ZL-1102; CB-001 | Phase 2 Clinical | Crescendo Biologics Ltd | Plaque psoriasis; Psoriasis | Details |
| CNTO-6785 | CNTO-6785; FTC-001 | Phase 1 Clinical | Johnson & Johnson Innovative Medicine, Morphosys Ag | Arthritis, Psoriatic; Arthritis, Rheumatoid; Psoriasis; Pulmonary Disease, Chronic Obstructive; Spondylitis, Ankylosing | Details |
| JNJ-61178104 | JNJ-61178104 | Phase 1 Clinical | Johnson & Johnson Innovative Medicine | Autoimmune Diseases | Details |
| Secukinumab biosimilar (BioRay Pharmaceutical) | BR-201 | Phase 1 Clinical | Zhejiang BioRay Biopharmaceuticals Co Ltd | Autoimmune Diseases; Plaque psoriasis; Psoriasis; Spondylitis, Ankylosing | Details |
| CT-P52 | CT-P52 | Phase 1 Clinical | Celltrion Inc | Details | |
| HGP-3918 | HGP-3918; HGP3918 | Phase 1 Clinical | Hitgen Inc | Inflammation | Details |
| JNJ-63823539 | JNJ-63823539 | Phase 1 Clinical | Johnson & Johnson Innovative Medicine | Arthritis, Rheumatoid | Details |
| BR-2021 | BR2021; BR-2021 | Phase 1 Clinical | Boryung Pharmaceutical Co Ltd | Pancreatic Neoplasms | Details |
| KYS-202004-A | KYS202004A; KYS-202004-A | Phase 1 Clinical | Jiangsu Kanion Pharmaceutical Co Ltd | Psoriasis | Details |
| Secukinumab biosimilar (Gan & Lee) | GLR1023; GLR-1023 | Phase 1 Clinical | Gan & Lee Pharmaceuticals | Plaque psoriasis | Details |
| anti-IL-17A humanized monoclonal antibody(Fontacea ) | Phase 1 Clinical | Shandong Fangtansi Biopharmaceutical Co Ltd | Plaque psoriasis | Details | |
| UA-026 | UA-026 | Phase 1 Clinical | Yousen Jianheng Biomedical (Shanghai) Co Ltd | Autoimmune Diseases; Plaque psoriasis; Psoriasis | Details |
| LEO-153339 | LEO-153339 | Phase 1 Clinical | Leo Pharma Inc | Details | |
| HY-1770 | HY-1770; HT-17; HT17; YF02; HT25; GH02; HY1770 | Phase 1 Clinical | Suzhou Pharmavan Co Ltd | Dermatitis, Atopic; Plaque psoriasis | Details |
| UCB-0159 | UCB-0159 | Phase 1 Clinical | Ucb Sa | Autoimmune Diseases | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Amdokitug | 608; SSGJ-608 | Approved | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | 益赛拓 | Mainland China | Plaque psoriasis | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | 2026-02-10 | Axial Spondyloarthritis; Non-radiographic axial spondyloarthritis; Plaque psoriasis; Psoriasis; Spondylarthritis; Spondylitis, Ankylosing | Details |
| Vunakizumab | SHR-1314 | Approved | Jiangsu Hengrui Medicine Co Ltd | 安达静 | Mainland China | Plaque psoriasis | Suzhou Suncadia Biopharmaceuticals Co Ltd | 2024-08-20 | Arthritis, Psoriatic; Autoimmune Diseases; Axial Spondyloarthritis; Graves Disease; Graves Ophthalmopathy; Lupus Nephritis; Non-radiographic axial spondyloarthritis; Plaque psoriasis; Psoriasis; Spondylarthritis; Spondylitis, Ankylosing | Details |
| Ixekizumab | LY-2439821 | Approved | Eli Lilly And Company | 拓咨, Taltz | United States | Psoriasis | Eli Lilly And Company | 2016-03-22 | Arthritis, Psoriatic; Arthritis, Rheumatoid; Axial Spondyloarthritis; Depressive Disorder, Major; Diabetes Mellitus, Type 1; Idiopathic Subglottic Stenosis; Lichen Planus; Non-radiographic axial spondyloarthritis; Pemphigoid, Bullous; Pityriasis Rubra Pilaris; Plaque psoriasis; Psoriasis; Pyoderma Gangrenosum; Spondylarthritis; Spondylitis, Ankylosing | Details |
| Xeligekimab | GR-1501 | Approved | Chongqing Genrix Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co Ltd | 金立希 | Mainland China | Plaque psoriasis | Chongqing Genrix Biopharmaceutical Co Ltd | 2024-08-20 | Axial Spondyloarthritis; Lupus Nephritis; Non-radiographic axial spondyloarthritis; Plaque psoriasis; Psoriasis; Spondylarthritis | Details |
| Virulizin | Approved | Aptose | Virulizin, Virulizin-2 gamma | Mexico | Colorectal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Uterine Cervical Neoplasms; Sarcoma, Kaposi; Melanoma; Carcinoma, Renal Cell | null | 1997-01-01 | Carcinoma, Renal Cell; Colorectal Neoplasms; Melanoma; Pancreatic Neoplasms; Sarcoma, Kaposi; Stomach Neoplasms; Uterine Cervical Neoplasms | Details | |
| Secukinumab | KB-03303A; NVP-AIN-457; AIN-457 | Approved | Novartis Pharma Ag | Cosentyx, 可善挺, Scapho | Japan | Arthritis, Psoriatic; Psoriasis | Novartis Pharma Ag | 2014-12-26 | Alopecia Areata; Arthritis; Arthritis, Juvenile; Arthritis, Psoriatic; Arthritis, Rheumatoid; Asthma; Axial Spondyloarthritis; Behcet Syndrome; Crohn Disease; Dermatitis, Atopic; Diabetes Mellitus, Type 1; Gastroenteritis; Giant Cell Arteritis; Graves Ophthalmopathy; Hidradenitis Suppurativa; Hyperkeratosis, Epidermolytic; Ichthyosiform Erythroderma, Congenital; Ichthyosis; Ichthyosis, Lamellar; Inflammation; Inflammatory Bowel Diseases; Lichen Planus; Lupus Erythematosus, Discoid; Lupus Nephritis; Melanoma; Metabolic Dysfunction-Associated Steatotic Liver Disease; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Necrobiosis Lipoidica; Netherton Syndrome; Non-radiographic axial spondyloarthritis; Palmoplantar pustulosis; Plaque psoriasis; Polymyalgia Rheumatica; Psoriasis; Pyoderma Gangrenosum; Rotator Cuff Injuries; Spondylarthritis; Spondylarthropathies; Spondylitis, Ankylosing; Tendinopathy; Tendon Injuries; Uveitis | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to: